...This article has been updated to correct Lee's role on the MorphoSys board. By BioCentury StaFF Corinne...
...and president of the U.S. business organization at Amgen Inc. (NASDAQ:AMGN). Cancer and autoimmune diseases play MorphoSys AG...
...his successor arrives, at which time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen...

...By STEPHEN HANSEN, ASSOCIATE EDITOR AND JEFF CRANMER, EXECUTIVE EDITOR A Cherry in MorphoSys’ hunt for new...
...platform to discover and develop T cell engaging therapeutics against up to six undisclosed targets. MorphoSys’...
...and gene therapy.TargetsENPP2 (ATX) - autotaxin BC Staff BBT-877 Affimed Roivant Sciences Insilico Medicine Inc. Johnson & Johnson Bridge Biotherapeutics Boehringer Ingelheim Cevec Pharmaceuticals GmbH MorphoSys ElevateBio...

...remain on the company’s board. Jens Holstein will step down as CFO and board member at MorphoSys AG...
...Hsieh was president and CEO of Meditope Biosciences Inc. BC Staff Thrive Earlier Detection Corp. Black Diamond Therapeutics Inc. MorphoSys AG Deep...

...in Europe (see “MorphoSys Nets $900M”).Under the deal, MorphoSys...
...and MorphoSys is eligible for tiered royalties.While MorphoSys’...
...MorphoSys.Kress added that over the long term MorphoSys...

...counsel. Previously, he held the same position at IQVia Holdings Inc. (NYSE:IQV). Veracyte also added MorphoSys AG...

...Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG...
...was the subject of the first major deal under MorphoSys’ new CEO Jean-Paul Kress (see “MorphoSys...

...ExeVir CEO Torsten Mummenbrauer told BioCentury. Mummenbrauer held BD roles at Hookipa Pharma Inc. (NASDAQ:HOOK), MorphoSys AG...

...lung cancer. EMA accepts tafasitamab MAA EMA accepted an MAA from Incyte Corp. (NASDAQ:INCY) and MorphoSys AG...
...Survival of motor neuron 2 centromeric Robin Sawka, BioCentury Staff Kadmon Holdings Inc. Sorrento Therapeutics Inc. Novartis AG AveXis Inc. Incyte Corp. MorphoSys AG Zentalis...

...Vicromax, its COVID-19 therapy (see “FDA Green-Lights More Than 70 COVID-19 Trials” ). Cancer company MorphoSys AG...
...Sawka, BioCentury Staff Frazier Healthcare Partners BioMarin Pharmaceutical Inc. Dicerna Pharmaceuticals Inc. Zogenix Inc. ADC Therapeutics S.A. Personal Genome Diagnostics Inc. Immunic Inc. MorphoSys AG Emergent...

...follow in the footsteps of other European mAb developers like Genmab A/S (CSE:GMAB; NASDAQ:GMAB) and MorphoSys AG...